Synonyms|Editors|Languages|Comments|Home|Sponsors|Health Information
 
  Gaucher's Disease 
  
Reviewed  02-25-2003  

Get Web page suited for printing
Email this to a friend or colleague
Studies with patients

Table of Contents (click to jump to sections)

What is Gaucher's Disease?
Is there any treatment?
What is the prognosis?
What research is being done?

Organizations
Related NINDS Publications and Information
Additional resources from MEDLINEplus

What is Gaucher's Disease?
Gaucher disease is an inherited metabolic disorder in which harmful quantities of a fatty substance called glucocerebroside accumulate in the spleen, liver, lungs, bone marrow, and, in rare cases, the brain. Three clinical forms (phenotypes) of Gaucher disease are commonly recognized. The first category, called type 1, is by far the most common. Patients in this group usually bruise easily and experience fatigue due to anemia, low blood platelets, enlargement of the liver and spleen, weakening of the skeleton, and in some instances, lung and kidney impairment. There are no signs of brain involvement. The onset of clinical manifestations may be early in life, or delayed until adulthood. The second group is classified as type 2. In this form, liver and spleen enlargement are apparent by 3 months of age. In addition, there is extensive and progressive brain damage. These patients usually die by 2 years of age. In the third category, called type 3, liver and spleen enlargement is variable, and signs of brain involvement such as seizures gradually become apparent. All of these patients exhibit a deficiency of an enzyme called glucocerebrosidase that catalyzes the first step in the biodegradation of glucocerebroside. Except for the brain, glucocerebroside arises mainly from the biodegradation of old red and white blood cells. In the brain, glucocerebroside arises from the turnover of complex lipids during brain development and the formation of the myelin sheath of nerves.

Is there any treatment?
Highly effective enzyme replacement therapy is available for patients with type 1 Gaucher disease. This therapy decreases liver and spleen size, reduces skeletal abnormalities, and successfully reverses other manifestations of the disorder including abnormal blood counts. There is currently no effective treatment for severe brain damage that may occur in patients with types 2 and 3.

What is the prognosis?
There is no permanent cure for Gaucher disease. Enzyme replacement therapy is very beneficial for type 1 patients and most of the type 3 patients with this condition.

What research is being done?
The NINDS is currently conducting a study to examine the skeletal response to enzyme replacement therapy in patients with type 1 whose spleens have been removed and its effect in patients with type 3 Gaucher disease with severe seizures.

Select this link to view a list of studies currently seeking patients.

 Organizations

National Gaucher Foundation
5410 Edson Lane
Suite 260
Rockville, MD 20852-3130
ngf@gaucherdisease.org
http://www.gaucherdisease.org
Tel: 301-816-1515 800-GAUCHER (428-2437)
Fax: 301-816-1516

Children's Gaucher Research Fund
P.O. Box 2123
Granite Bay, CA 95746-2123
research@childrensgaucher.org
http://www.childrensgaucher.org
Tel: 916-797-3700
Fax: 916-797-3707

National Organization for Rare Disorders (NORD)
P.O. Box 1968
(55 Kenosia Avenue)
Danbury, CT 06813-1968
orphan@rarediseases.org
http://www.rarediseases.org
Tel: 203-744-0100 Voice Mail 800-999-NORD (6673)
Fax: 203-798-2291

National Tay-Sachs and Allied Diseases Association
2001 Beacon Street
Suite 204
Boston, MA 02135
info@ntsad.org
http://www.ntsad.org
Tel: 617-277-4463 800-90-NTSAD (906-8723)
Fax: 617-277-0134

Related NINDS Publications and Information

  • Patients with Neuronopathic Gaucher Disease Sought for Study

  • Lay-language descriptions of new NINDS program announcements, requests for applications, and clinical studies seeking patients.


    NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

    All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.


    Provided by:
    The National Institute of Neurological Disorders and Stroke
    National Institutes of Health
    Bethesda, MD 20892




    Return to top


    Home | About NINDS | Disorders | Funding | News & Events | Find People | Jobs & Training | Accessibility

    H H S Logo - link to U. S. Department of Health and Human Services     N I H logo - link to U. S. National Institutes of Health    N I N D S logo - link to National Institute of Neurological Disorders and Stroke    FirstGov Logo - link To FirstGov